Mariner’s Solid Biosciences SLDB Stock Holding History

Mariner’s Portfolio SLDB Stock Details SLDB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-19,414	Closed	-$94.5K	–	3744
2025 Q2	$94.5K	Buy	+19,414	New	+$68.6K	﹤0.01%	3256

Other funds holding SLDB

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Mariner's SLDB Position: Q3 2025 in Review

Mariner sold out of Solid Biosciences (SLDB) in Q3 2025, closing a stake of 19,414 shares — an estimated $94.5K sold.

Mariner first reported a position in SLDB in Q2 2025 and held it in 1 quarter. The position peaked at $94.5K in Q2 2025. 127 funds tracked by Wall St. Rank hold SLDB as of Q3 2025.

Mariner reported no remaining Solid Biosciences position as of Q3 2025 after selling out during the quarter.
Mariner sold 19,414 Solid Biosciences shares in Q3 2025, an estimated $94.5K.
Mariner first reported a position in Solid Biosciences in Q2 2025 and held it in 1 quarter.
Mariner's Solid Biosciences position peaked at $94.5K in Q2 2025.
127 funds tracked by Wall St. Rank held Solid Biosciences as of Q3 2025.

Based on Mariner's 13F filing for Q3 2025, filed 14 Nov 2025.